Menu
Recruiting NCT06696534

Exploring Participant Preference for Screening Methods and Experience Into Colorectal Cancer Screening Programme

No phase Interventional Screening for Colon Cancer Survey and Questionnaire

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Survey using a questionnaire., Survey using a questionnaire..
Who it may be relevant to
Registry conditions: Screening for Colon Cancer, Survey and Questionnaire. Basic parameters: 50 years — 69 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Portugal, Spain
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Overview

The goal of this low-risk interventional study is to analyze participants' assessment of colorectal cancer screening program through screening method preference and experience after FOBT analysis in screaned participant population for colorectal cancer; could include any of the following: both sexes, age 50-69 years, asympthomatic volunteers. The main aims to answer are: * Values of experience of participants into screening programme. * Values of preferences of participants for screening methods. Participants will answer two questionnaires and they'll be given their information and clinical data to investigator or health personnel.

Interventions

  • Other Survey using a questionnaire.
    Preference questionnaire for colorectal cancer screening methods
  • Other Survey using a questionnaire.
    Experience questionnaire into colorectal cancer screening programme

Primary outcome measures

  • Value of questionnaires into screening programme [Time frame: 12 months]

Eligibility criteria

Inclusion criteria

  • Participants ages from 50 to 69 years (both included) at the time of informed consent signed.
  • Participants invited to participate in population-based screening programme who are eligible to undertake FOBT at the Primary Health Care Center.
  • Participants should sign an informed consent. They must understand the nature, significance, implications, and risks of the clinical study before signing the informed consent form.

Exclusion criteria

  • Participants who have not delivery a stool sample in the Primary Health Care Center before signing the informed consent form.
  • Participants with a previous colonoscopy in consequence of a FOBT positive result.
  • Participants who are in a dependent personal or non-medical relationship with the Sponsor or the Investigators.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Screening

Study locations

Portugal · 1 center
  • UCSP Sete Rios — Lisbon
Spain · 1 center
  • CS Mar Báltico — Madrid

Publications

  • Adler A, Geiger S, Keil A, Bias H, Schatz P, deVos T, Dhein J, Zimmermann M, Tauber R, Wiedenmann B. Improving compliance to colorectal cancer screening using blood and stool based tests in patients refusing screening colonoscopy in Germany. BMC Gastroenterol. 2014 Oct 17;14:183. doi: 10.1186/1471-230X-14-183. PMID 25326034
  • De Angelis R, Demuru E, Baili P, Troussard X, Katalinic A, Chirlaque Lopez MD, Innos K, Santaquilani M, Blum M, Ventura L, Paapsi K, Galasso R, Guevara M, Randi G, Bettio M, Botta L, Guzzinati S, Dal Maso L, Rossi S; EUROCARE-6 Working Group. Complete cancer prevalence in Europe in 2020 by disease duration and country (EUROCARE-6): a population-based study. Lancet Oncol. 2024 Mar;25(3):293-307. do PMID 38307102
  • Siegel RL, Wagle NS, Cercek A, Smith RA, Jemal A. Colorectal cancer statistics, 2023. CA Cancer J Clin. 2023 May-Jun;73(3):233-254. doi: 10.3322/caac.21772. Epub 2023 Mar 1. PMID 36856579

Identifiers

NCT: NCT06696534 · AMD-CCR-2024-01 · 2024-NDMH-5101_240046

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗